Lilly's obesity drug shows strong weight loss but fails to demonstrate cardiovascular benefit in heart disease trial

Eli Lilly released Phase 3 results for its next‑generation obesity therapy retatrutide, showing it produces substantial weight loss in a trial of nearly 2,000 participants with severe obesity and established heart disease.

While the magnitude of weight loss was highlighted, the study did not answer the key question of whether the drug lowers cardiovascular events, leaving a critical gap in the evidence needed for clinicians and regulators.

The absence of cardiovascular outcome data may affect the drug’s future positioning, especially as Medicare beneficiaries increasingly choose injectable GLP‑1 agents over oral formulations.